Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 10, 1999, Pages 2554-2562

  Feuerstein, Giora Z ^a   Patel, Arun ^b   Toomey, John R ^a   Bugelski, Peter ^b   Nichols, Andrew J ^a   Church, William R ^c   Valocik, Richard ^a   Koster, Paul ^a   Baker, Audrey ^b   Blackburn, Michael N ^a,b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Department of Protein Biochemistry ^*  (United States)

^c Green Mountain Antibodies   (United States)

Author keywords

Aspirin; Coagulation; Factor IX; Heparin; Monoclonal antibodies; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 9; HEPARIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BC2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ARTICLE; DOSE RESPONSE; DRUG EFFICACY; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

EID: 0032833319     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.10.2554     Document Type: Article

References (27)

1. Schror K. Antiplatelet drugs: A comprehensive review. Drugs. 1995; 50:7-28.
2. Wood AJJ. Aspirin, heparin and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med. 1997;336:847-860.
3. Feuerstein G, Ruffolo RR Jr. A novel anti-platelet drug for prevention of thrombotic disorders. Exp Opinion Invest New Drugs. 1994;3:1163-1170.
4. Feuerstein G, Ruffolo RR Jr. Clopidogrel-pharmacological profile of a novel anti-thrombotic agent. Exp Opinion Invest New Drugs. 1995;4: 425-430.
5. Thomas DP. Does low molecular weight heparin cause less bleeding? Thromb Haemost. 1997;78:1422-1425.
6. Hirsch J, Sirangusa S, Cosmi B, Ginsberg JS. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb Haemost. 1995;74:360-363.
7. Topol EJ. Toward new frontier in myocardial reperfusion therapy: Emerging platelet pre-eminence. Circulation. 1997;97:211-218.
8. The EPIC Investigators. Use of a monoclonal antibody directed against the glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
9. EPILOG Investigators. Effect of the platelet glycoprotein IIb/IIIa receptor inhibitor, abciximab, with lower heparin dosages on ischemic complications of percutaneous coronary revascularization. N Engl J Med. 1997; 336:1689-1696.
10. The Gusto II Angioplasty Substudy Investigators. A clinical trial comparing primary angioplasty with tissue plasminogen activator and recombinant hirudin with heparin for acute myocardial infarction. N Engl J Med. 1997;336:1621-1628.
11. Schumacher WA, Heran CL, Steinbacher TE. Low molecular weight heparin (fragmin) and thrombin active site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time. J Cardiovasc Pharmacol. 1996;28:19-25.
12. Roberts HR. Molecular biology of hemophilia B. Thromb Haemostas. 1993;70:1-9.
13. Hoffman M, Monroe DM, Oliver JA, Roberts HR. Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood. 1995;86:1794-1801.
14. Mann KG, Kalafatis M. The coagulation explosion. Cerebrovasc Dis. 1995;5:93-97.
15. McGraw RA, Davis L, Lundblad RL, Stafford DW, Roberts HR. Structure and function of FIX: Defects in hemophilia B. Clin Hematol. 1985;14:359-385.
16. Lollar P, Fass DN. Inhibition of activated porcine factor IX by dansyl-glutamyl-glycyl-arginyl-chloromethylketone. Arch Biochem Biophys. 1984;233:438-446.
17. Benedict CR, Ryan J, Wolitzky B, Ramos R, Gerlach M, Tijburg P, Stern D. Active site-blocked Factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J Clin Invest. 1991;88:1760-1765.
18. Bajaj SP, Rapaport SI, Maki SL. A monoclonal antibody to factor IX that inhibits the factor VIII: Ca potentiation of factor X activation. J Biol Chem. 1985;260:11574-11580.
19. Jenny R, Church W, Odegaard B, Litwiller R, Mann K. Purification of six human vitamin-K dependent proteins in a single chromatographic step using immunoaffinity columns. Prep Biochem. 1986;16:227-245.
20. Jenny RJ, Messier TL, Ouellette LA, Church WR. Immunochemical techniques for studying coagulation proteins. Meth Enzymol. 1993;222: 400-416.
21. Nesheim M, Blackburn MN, Lawler CM, Mann KG. Dependence of antithrombin III and thrombin binding stoichiometries and catalytic activity on the molecular weight of affinity purified heparin. J Biol Chem. 1986;261:3214-3221.
22. Kurz KD, Main BW, Santusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res. 1990;60:269-280.
23. Dejana E, Villa S, De Gaetano G. Bleeding time in rats: A comparison of different experimental conditions. Thromb Haemost. 1982;48:108-111.
24. Luchtman-Jones L, Broze GJ. The current status of coagulation. Ann Med. 1995;27:47-52.
25. Verstraete M. New developments in antiplatelet and antithrombotic therapy. Eur Heart J. 1995;16:16-23.
26. Bauer K, Kass B, Ten Cate H, Hawiger J, Rosenberg R. Factor IX is activated in vivo by the tissue factor mechanism. Blood. 1990;76: 731-736.
27. Spanier TB, Oz MC, Minanov OP, Simantov R, Kisiel W, Stern DM, Rose EA, Schmidt AM. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: A preliminary study on the dog. J Thorac Cardiovasc Surg. 1998;115:1179-1188.